New drugs in recurrent high grade gliomas

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 1913-1920

  Brandes, Alba Ariela ^a   Pasetto, Lara Maria ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Brain tumors; Chemotherapy; Glioblastoma; Recurrence; Review

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ANTINEOPLASTIC AGENT; GOSSYPOL; IDARUBICIN; IRINOTECAN; PACLITAXEL; PHENYLACETIC ACID; PROCARBAZINE; RETINOIC ACID; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG MECHANISM; EDEMA; GLIOMA; HUMAN; HYPOKALEMIA; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CARUBICIN; CLINICAL TRIALS; DACARBAZINE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; GLIOMA; GOSSYPOL; HUMANS; IDARUBICIN; ISOTRETINOIN; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PHENYLACETATES; TAMOXIFEN; TOPOTECAN;

EID: 0033898418     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Boring CC, Squires TS and Tong T et al: Cancer statistics. Cancer 43: 7-26, 1993.
2. Moller-Jensen O, Esteve J and Moller H et al: Cancer in the European Community and its Member States. Eur J Cancer 26: 1167-1256, 1990.
3. Brandes A and Fiorentino M: The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Investigation 14 (6): 551-559, 1996.
4. Lowe P, Sanson C and Schwalbe C et al: Antitumor imidazotetrazine 25. Crystal structure of 8-carbamyl-3-methylimidazo5,1-D-1,2,3,5-tetrazin-4-(3H)-one (temozolomide) and structural comparisons with related drugs mitozolomide and DTIC. J Med Chemistry 35: 3377, 1992.
5. O'Reilly S, Newlands E and Brown G et al: Investigation of human in vivo tissue and tumor pharmacokinetics and mechanism of action of temozolomide. Br J Cancer 69: 23, 1994.
6. Patel M, McCully C and Godwin K et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Society Clin Oncol 14: 461, 1995.
7. Belanich M, Randall T and Pastor M et al: Intracellular localization and intracellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 37: 547, 1996.
8. Wedge S, Porteous J and May B et al: Potentiation of temozolomide cytotoxicity by an inhibitor of alkylguanine-DNA-alkyltransferase. J Cell Biochem 21: 295, 1995.
9. Durkacz BW, Omidiji O and Gray DA et al: (ADP-ribose) participates in DNA excision repair. Nature 238: 593, 1980.
10. Boulton S, Pemberton LC and Porteous JK et al: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72: 849, 1995.
11. Friedman HS, Mc Lendon RE and Kerby T et al: DNA mismatch repair and O6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998.
12. Raimond E, Izbicka E and Soda H et al: Activity of temozolomide against human tumor colony forming units. Clin Cancer Res 3: 1769, 1997.
13. Friedman HS, Dolan ME and Pegg AE et al: Activity of temozolomide in treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857, 1995.
14. Newlands ES, O'Reilly SM and Glaser MG et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32 A: 2236-2241, 1996.
15. Bower ES, Newlands NM and Bleehen M et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488, 1997.
16. Paulsen F, Hoffmann W, Becker G and Belka C, Weinmann M, Classen J, Kortmann RD, Bamberg M: Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125: 411-418, 1999.
17. Yung A, Levin VA, and Albright R et al: Randomized trial of temodal (TEM) vs procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc ASCO 18: 139 A, 1999.
18. Yung A, Prados M and Yaya-Tur R et al: Multicenter phase-2 trial of temozolomide in patient with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17: 2762-2771, 1999.
19. Brandes AA, Pasetto LM and Monfardini S. Temozolomide in high grade gliomas at second relapse: a phase II study Proc ASCO 2000.
20. Slichenmyer WJ, Rowinsky EK, Grochow LB et al: Camptothecin analogous: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34: 53-57, 1994.
21. Gupta E, Mick R and Ramirez J et al: Pharmacokinetic and pharmacodynamic evaluation of topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15: 1502-1510, 1997.
22. Rivory LP, Haaz M-C and Canal P et al: Pharmacokinetic interrelationship of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3: 1261-1266, 1997.
23. Coggins CA, Elion GB and Houghton PJ et al: Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41: 485-490, 1998.
24. Friedman HS, Petros WP and Friedman AH et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 (5): 1516-1525, 1999.
25. Mc Cabe FI and Johnson RL: Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 12: 308, 1994.
26. Kuhn JJ, Rizzo J and Eckardt J et al: Phase I bioavailability study of oral topotecan. Proc ASCO 14: 474, 1995.
27. Friedman HS, Kerby T and Fields S et al: Topotecan treatment of adult with primary malignant glioma. Cancer 85 (5): 1160-1165, 1999.
28. Kadota RP, Stewart CF and Horn M et al: Topotecan for the treatment of recurrent or progressive central nervous system tumors -a pediatric oncology group phase II study. J Neuro-Oncol 43: 43-47, 1999.
29. Macdonald D, Cairncross G and Stewart D et al: Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7: 205-207, 1996.
30. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci 90: 9552, 1993.
31. Rowinsky EK and Donchower RC: Drug therapy paclitaxel (Taxol). N Engl J Med 332: 1004, 1996.
32. Chamberlain MC and Kormanik P: Salvage chemotherapy with Taxol for recurrent anaplastic astrocytomas. J Neuro-Oncol 43: 71-78, 1999.
33. Gillies HC, Herriott D and Liang R et al: Pharmacokinetics of idarubicin (4-demethoxy-daunorubicin) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 23: 303-310, 1987.
34. Zanette L, Zucchetti M and Freschi A et al: Pharmacokinetics of 4-demethoxydaunorubian in cancer patients. Cancer Chemother Pharmacol 25: 445-448, 1990.
35. Speth PA, Minderman H and Haanen C: Idarubicin v. daunorubicin: preclinical and clinical pharmacokinetics studies. Semin Oncol 16: 2-9, 1989.
36. Ardnt CAS, Krailo MD and Steinherz L et al: A phase II clinical trial of idaruhicin administered to children with relapsed brain tumors. Cancer 83(4): 813-816, 1998.
37. Kuratsu JI, Arita N and Kurisu K et al: A phase II study of KRN8602 (MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma. J Neuro-Oncol 42: 177-181, 1999.
38. Yung WKA, Kyritsis AP and Gleason MJ et al: Treatment of recurrent malignant glioma with high dose 13-cis-Retinoic. Acid Clin Cancer Res 2: 1931-1935, 1996.
39. Vertosick FT, Selker RG and Randall MS et at: A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neuroncol 19: 97-103, 1994.
40. Baltuch GH, Couldwell WT and Villemure JG et al: Protein Kinase C inhibitors suppress cell growth in established and low passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993.
41. Lien EA, Wester K and Lonning PE et al: Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641-645, 1991.
42. Couldwell WT, Weiss MH and De Giorgio CM et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high dose tamoxifen. Neurosurgery 32: 485-490, 1993.
43. Vertosick FT, Selker RG and Pollack IF et al: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30: 897-903, 1992.
44. Couldwell WT, Hinton DR and Surnock AA et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen: Advances in brief. Clin Cancer Res 2: 619-622, 1996.
45. Brandes A, Ermani M and Turazzi S et al: Procarbazine and high-dose tamoxifen as a second line regimen in recurrent high-grade gliomas: A phase II study. J Clin Oncol 17(2): 645-650, 1999.
46. Bushunow P, Reidenberg M, Wasenko J et al: Gossypol treatment of recurrent adult malignant gliomas. J Neuro-Oncol 43: 79-86, 1999.
47. Thibault A, Cooper MR and Figg WD et al: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690, 1994.
48. Stockhammer G, Manley GT and Johnson R et al. Inhibition of proliferation and induction of differentiation in medulloblastoma and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 83: 672-681, 1995.
49. Ram Z, Samid D and Walbridge S et al: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54: 2927-2934, 1994.
50. Chang SM, Kuhn JG and Robins I et al: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Report: J Clin Oncol 13 (3): 984-990, 1999.
51. Eckhardt SG, Atkins Y and Agarwala SS et al: A phase I study of temozolomide combined with cisplatin (CDDP) in patient with advanced cancer. Proc ASCO 16: 136, 1997.